Standout Papers

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results 2023 2026 2024149
  1. Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results (2023)
    Sham Mailankody, Jeffrey Matous et al. Nature Medicine

Immediate Impact

1 from Science/Nature 59 standout
Sub-graph 1 of 24

Citing Papers

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges
2025 Standout
Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors
2025 Standout
1 intermediate paper

Works of Erin E. Karski being referenced

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
2023 Standout
NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
2019

Author Peers

Author Last Decade Papers Cites
Erin E. Karski 241 36 144 95 13 371
Diana Steppan 93 31 145 169 12 390
George Mo 158 21 86 48 17 318
H. A. Fritsche 163 61 94 80 12 374
Stefan Habringer 164 30 103 38 18 338
Stanley J. Oiseth 158 26 67 102 9 382
Laura Rodríguez‐Romo 129 16 93 102 18 389
Keimei Nakano 56 28 126 74 15 387
Philip Hamann 92 29 91 51 16 407
Fabio Canal 177 13 130 91 18 381
Sohail Qayyum 145 18 150 31 13 363

All Works

Loading papers...

Rankless by CCL
2026